Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?

A. Y. Babenko, V. K. Bayrasheva
2015 Medical Council  
The beginning of XXI century in diabetology is characterized by a major breakthrough in the development of new pharmacological agents and new approaches to the treatment of type 2 diabetes. The move from glucose-centric to multifactorial concept of treatment and creation of the new groups of antidiabetic drugs with multiple properties not effecting glycemia have considerably complicated though greatly improved practitioner's choice of therapy for an individual patient. This undoubtedly calls
more » ... ndoubtedly calls for a greater knowledge of specialists about non-glycemic effects of antidiabetic drugs. This review is devoted to renoprotective effect demonstrated by various groups of antidiabetic drugs, focusing on new groups of drugs included in the Russian algorithms over the past decade (GLP-1 receptor agonists, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors). It can be useful to both researchers and clinicians who are striving to offer the therapy of choice to their patients today.
doi:10.21518/2079-701x-2015-7-32-43 doaj:fb5a27b6411148db945b098afe39897b fatcat:r7jncg3zwfg6zfwkavqkr4u5ky